Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome
Emma H. Kaplan
, Elizabeth A. Offermann
, Jacqueline W. Sievers
,
Anne Marie Spalding Comi
Kennedy Krieger Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
38
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Sturge-Weber Syndrome
100%
Refractory Seizures
100%
Cannabidiol
100%
Brain Involvement
33%
Seizure Frequency
16%
Cognitive Impairment
16%
Adverse Events
16%
Quality of Life
16%
Adjunctive Therapy
16%
Refractory Epilepsy
16%
Life Events
16%
Quality of Life Improvement
16%
Seizure Reduction
16%
Lack of Efficacy
16%
Cannabinoids
16%
Vascular Malformation
16%
Maintenance Dose
16%
Drug-resistant Epilepsy
16%
Anticonvulsant Action
16%
Leptomeningeal
16%
Neuroprotective Action
16%
Antioxidant Activity
16%
Seizure Management
16%
Frequency Quality
16%
Motor Seizures
16%
Well Tolerated
16%
Medicine and Dentistry
Epileptic Seizure
100%
Sturge-Weber Syndrome
100%
Cannabidiol
100%
Quality of Life
33%
Apoplexy
16%
Antioxidant
16%
Epilepsy
16%
Cognitive Defect
16%
Low Drug Dose
16%
Neuroprotective Agent
16%
Anticonvulsant
16%
Vascular Anomaly
16%
Maintenance Drug Dose
16%
Intractable Epilepsy
16%
Drug Resistant Epilepsy
16%
Cannabinoid
16%
Side Effect
16%
Adverse Event
16%
Pharmacology, Toxicology and Pharmaceutical Science
Sturge Weber Syndrome
100%
Cannabidiol
100%
Adverse Event
16%
Anticonvulsive Agent
16%
Neuroprotective Agent
16%
Antioxidant
16%
Epilepsy
16%
Cerebrovascular Accident
16%
Maintenance Dose
16%
Cognitive Defect
16%
Intractable Epilepsy
16%
Drug Resistant Epilepsy
16%
Congenital Blood Vessel Malformation
16%
Cannabinoid
16%
Side Effect
16%
Low Drug Dose
16%
Neuroscience
Cannabidiol
100%
Quality of Life
33%
Cognitive Disorders
16%
Antioxidant
16%
Neuroprotective Agent
16%
Cerebrovascular Accident
16%
Cannabinoid
16%
Anticonvulsant
16%
Side Effect
16%
Drug Resistant Epilepsy
16%
Epilepsy
16%